Acerus Pharmaceuticals (FRA:3TP0) Total Liabilities : €62.18 Mil (As of Sep. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Acerus Pharmaceuticals Total Liabilities?

Acerus Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2022 was €62.18 Mil.

Acerus Pharmaceuticals's quarterly Total Liabilities increased from Mar. 2022 (€47.56 Mil) to Jun. 2022 (€54.06 Mil) and increased from Jun. 2022 (€54.06 Mil) to Sep. 2022 (€62.18 Mil).

Acerus Pharmaceuticals's annual Total Liabilities declined from Dec. 2019 (€25.44 Mil) to Dec. 2020 (€11.36 Mil) but then increased from Dec. 2020 (€11.36 Mil) to Dec. 2021 (€31.56 Mil).

Acerus Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Acerus Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acerus Pharmaceuticals Total Liabilities Chart

Acerus Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Liabilities

Get a 7-Day Free Trial

7.24

14.85

25.44

11.36

31.56

Acerus Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Total Liabilities	Get a 7-Day Free Trial															25.46	31.56	47.56	54.06	62.18

Acerus Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Acerus Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2021 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	10.685	+	(18.972	+	1.907
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	31.56

Total Liabilities	=	Total Assets (A: Dec. 2021 )	-	Total Equity (A: Dec. 2021 )
	=	8.542	-	-23.022
	=	31.56

Acerus Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	15.607	+	(46.569	+	0.0049999999999955
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	62.18

Total Liabilities	=	Total Assets (Q: Sep. 2022 )	-	Total Equity (Q: Sep. 2022 )
	=	48.147	-	-14.034
	=	62.18

Acerus Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Acerus Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Acerus Pharmaceuticals (FRA:3TP0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acerus Pharmaceuticals Corp (FRA:3TP0) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

7025 Langer Drive, Suite 205, Mississauga, ON, CAN, L5N 0E8

Website

https://www.aceruspharma.com

Acerus Pharmaceuticals Corp is a specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of branded products that improve patient experience, with a primary focus on the field of men's health. Its foundational product includes NATESTO, a testosterone therapy based on nasal gel technology. The company commercializes its products via its salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.

Acerus Pharmaceuticals (FRA:3TP0) Headlines

No Headlines